2022至2023年欧洲新生儿重症监护病房红细胞输注实践
该国际前瞻性观察性队列研究于2022年9月1日至2023年8月31日收集22个欧洲国家64个新生儿重症监护病房(NICU)的数据,每中心观察6周,纳入1143例胎龄<32周的早产儿。主要结局包括红细胞输注患病率、累积发生率、指征、输血前血红蛋白(Hb)水平、剂量、输注速率、Hb增量及不良反应。结果显示,生后1至28天总体红细胞输注患病率为每100个入院日3.4个输血日,国家间差异大,仅部分由患者构成解释;至第28天,36.5%(95%CI 31.6%-41.5%)的婴儿至少接受1次输血。大多数输血(748/903,82.8%)基于明确的Hb阈值,但其中44.4%(324/729)的输血前Hb低于ETTNO限制性阈值,36.4%(265/729)低于TOP限制性阈值;分别有48.3%(352/729)和56.1%(409/729)的输血前Hb处于限制性与宽松性阈值之间,7.3%(53/729)和7.5%(55/729)高于宽松性阈值。基于阈值的输血中,多数剂量为15 mL/kg(470/738,63.7%),输注时间3小时(400/738,54.2%),但剂量和持续时间变异大。作者认为,这些结果强调需要优化实践并开展实施研究以支持证据转化。
要点
- 至生后第28天,36.5%(95%CI 31.6%-41.5%)的胎龄<32周早产儿至少接受1次红细胞输注。
- 基于Hb阈值的输血中,44.4%(324/729)的输血前Hb低于ETTNO限制性阈值,36.4%(265/729)低于TOP限制性阈值。
- 基于Hb阈值的输血中,48.3%(352/729)和56.1%(409/729)的输血前Hb分别处于ETTNO和TOP限制性与宽松性阈值之间。
- 基于Hb阈值的输血中,63.7%(470/738)剂量为15 mL/kg,54.2%(400/738)输注时间3小时,但剂量和持续时间变异大。
- 生后1至28天总体红细胞输注患病率为每100个入院日3.4个输血日,国家间差异大,仅部分由患者构成解释。
适用人群与场景
- 胎龄<32周的早产儿,入住22个欧洲国家64个新生儿重症监护病房(NICU)。
- 研究期间为2022年9月1日至2023年8月31日,每中心观察6周。
研究设计与关键结果
- 研究类型:国际前瞻性观察性队列研究,纳入1143例胎龄<32周早产儿(641例男性[56.1%];中位胎龄28周加2天[IQR 26周加2天至30周加2天];中位出生体重1030[IQR 780-1350]g),其中396例接受1次或以上红细胞输注,共计903次输血。
- 生后1至28天总体红细胞输注患病率为每100个入院日3.4个输血日,国家间差异大,仅部分由患者构成解释。
- 至第28天,36.5%(95%CI 31.6%-41.5%)的婴儿至少接受1次输血。
- 大多数输血基于明确的Hb阈值(748/903,82.8%)。
- 基于阈值的输血中,输血前Hb低于ETTNO限制性阈值者324/729(44.4%),低于TOP限制性阈值者265/729(36.4%)。
- 基于阈值的输血中,输血前Hb处于限制性与宽松性阈值之间者,按ETTNO为352/729(48.3%),按TOP为409/729(56.1%);高于宽松性阈值者分别为53/729(7.3%)和55/729(7.5%)。
- 基于阈值的输血中,剂量为15 mL/kg者470/738(63.7%),输注时间3小时者400/738(54.2%),但剂量和持续时间存在较大变异。
证据类型、等级与局限
- 证据类型:国际前瞻性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些结果强调需要优化实践,并需要实施研究以支持证据转化。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Red blood cell (RBC) transfusions are frequently administered to preterm infants born before 32 weeks of gestation in the neonatal intensive care unit (NICU). Two randomized clinical trials (Effects of Transfusion Thresholds on Neurocognitive Outcomes of Extremely Low-Birth-Weight Infants [ETTNO] and Transfusion of Prematures [TOP]) found that liberal RBC transfusion thresholds are nonsuperior to restrictive thresholds, but the extent to which these results have been integrated into clinical practice since publication in 2020 is unknown.
OBJECTIVE: To describe neonatal RBC transfusion practice in Europe.
DESIGN, SETTING, AND PARTICIPANTS: This international prospective observational cohort study collected data between September 1, 2022, and August 31, 2023, with a 6-week observation period per center, from 64 NICUs in 22 European countries. Participants included 1143 preterm infants born before 32 weeks of gestation.
EXPOSURE: Admission to the NICU.
MAIN OUTCOMES AND MEASURES: Study outcome measures included RBC transfusion prevalence rates, cumulative incidence, indications, pretransfusion hemoglobin (Hb) levels, volumes, and transfusion rates, Hb increment, and adverse effects of RBC transfusion.
RESULTS: A total of 1143 preterm infants were included (641 male [56.1%]; median gestational age at birth, 28 weeks plus 2 days [IQR, 26 weeks plus 2 days to 30 weeks plus 2 days]; median birth weight, 1030 [IQR, 780-1350] g), of whom 396 received 1 or more RBC transfusions, totaling 903 transfusions. Overall RBC transfusion prevalence rate during postnatal days 1 to 28 was 3.4 transfusion days per 100 admission days, with considerable variation across countries, only partly explained by patient mix. By day 28, 36.5% (95% CI, 31.6%-41.5%) of infants had received at least 1 transfusion. Most transfusions were given based on a defined Hb threshold (748 [82.8%]). Hemoglobin levels before transfusions indicated for threshold were below the restrictive thresholds set by ETTNO in 324 of 729 transfusions (44.4%) and TOP in 265 of 729 (36.4%). Conversely, they were between restrictive and liberal thresholds in 352 (48.3%) and 409 (56.1%) transfusions, respectively, and above liberal thresholds in 53 (7.3%) and 55 (7.5%) transfusions, respectively. Most transfusions given based on threshold had volumes of 15 mL/kg (470 of 738 [63.7%]) and were administered over 3 hours (400 of 738 [54.2%]), but there was substantial variation in dose and duration.
CONCLUSIONS AND RELEVANCE: In this cohort study of very preterm infants, most transfusions indicated for threshold were given for pretransfusion Hb levels above restrictive transfusion thresholds evaluated in recent trials. These results underline the need to optimize practices and for implementation research to support uptake of evidence.
参考来源
- Houben NAM, Fustolo-Gunnink S, Fijnvandraat K, et al. Red Blood Cell Transfusion in European Neonatal Intensive Care Units, 2022 to 2023. JAMA Netw Open. 2024. PMID: 39298172. doi:10.1001/jamanetworkopen.2024.34077
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。